Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo

Carcinogenesis

Volumn 31, Issue 5, 2009, Pages 911-917

  Jung, Sung Keun ^a,b,c   Lee, Ki Won ^b   Byun, Sanguine ^a,b,c   Lee, Eun Jung ^a   Kim, Jong Eun ^a,c   Bode, Ann M ^c   Dong, Zigang ^c   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYRICETIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P70; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; FLAVONOID; HIF1A PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN TUMOR; ULTRAVIOLET B RADIATION; WESTERN BLOTTING; ANIMAL; HAIRLESS MOUSE; METABOLISM; PHOSPHORYLATION; ULTRAVIOLET RADIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MICE; MICE, HAIRLESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; ULTRAVIOLET RAYS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952317417     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp221     Document Type: Article

References (50)

1. Folkman,J. (1995) Seminars in Medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763.
2. Bergers,G. et al. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401-410.
3. Carmeliet,P. et al. (2000) Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
4. Liekens,S. et al. (2001) Angiogenesis: regulators and clinical applications. Biochem. Pharmacol., 61, 253-270.
5. Detmar,M. et al. (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol., 111, 1-6.
6. Surazynski,A. et al. (2008) Extracellular matrix and HIF-1 signaling: the role of prolidase. Int. J. Cancer, 122, 1435-1440.
7. Forsythe,J.A. et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16, 4604-4613.
8. Olsson,A.K. et al. (2006) VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol., 7, 359-371.
9. Liao,D. et al. (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev., 26, 281-290.
10. Iyer,N.V. et al. (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev., 12, 149-162.
11. Ryan,H.E. et al. (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J., 17, 3005-3015.
12. Strieter,R.M. (2005) Masters of angiogenesis. Nat. Med., 11, 925-927.
13. Li,Y. et al. (2006) UVB radiation induces expression of HIF-1alpha and VEGF through the EGFR/PI3K/DEC1 pathway. Int. J. Mol. Med., 18, 713-719.
14. Jiang,B.H. et al. (2008) AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets, 8, 19-26.
15. Surh,Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 3, 768-780.
16. Hakkinen,S.H. et al. (1999) Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem., 47, 2274-2279.
17. Ribeiro de Lima,M.T. et al. (1999) Determination of stilbenes (transastringin, cis- and trans-piceid, and cis- and trans-resveratrol) in Portuguese wines. J. Agric. Food Chem., 47, 2666-2670.
18. Sellappan,S. et al. (2002) Flavonoids and antioxidant capacity of Georgiagrown Vidalia onions. J. Agric. Food Chem., 50, 5338-5342.
19. Lu,J. et al. (2006) Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res., 66, 4410-4418.
20. Lee,K.W. et al. (2007) Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis, 28, 1918-1927.
21. Ko,C.H. et al. (2005) Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol. Cancer Ther., 4, 281-290.
22. Jung,S.K. et al. (2008) Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res., 68, 6021-6029.
23. Ding,M. et al. (2006) Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J. Biol. Chem., 281, 17359-17368.
24. Albini,A. et al. (2005) Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res., 65, 10637-10641.
25. DeLisser,H.M. et al. (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am. J. Pathol., 151, 671-677.
26. DiMaio,T.A. et al. (2008) PECAM-1 isoform-specific functions in PECAM-1-deficient brain microvascular endothelial cells. Microvasc. Res., 75, 188-201.
27. Harris,A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
28. Miyoshi,A. et al. (2006) Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int. J. Oncol., 29, 1533-1539.
29. Mylonis,I. et al. (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1 alpha. J. Biol. Chem., 281, 33095-33106.
30. Gao,N. et al. (2004) Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell. Biochem., 255, 33-45.
31. Hanahan,D. et al. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
32. Nijsten,T. et al. (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br. J. Dermatol., 151, 837-845.
33. Newell,B. et al. (2003) Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry. Br. J. Dermatol., 149, 105-110.
34. Li,V.W. et al. (2008) Antiangiogenesis in the treatment of skin cancer. J. Drugs Dermatol., 7, s17-s24.
35. Tosetti,F. et al. (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J., 16, 2-14.
36. Mukhtar,H. et al. (1988) Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a)anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res., 48, 2361-2365.
37. Claffey,K.P. et al. (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res., 56, 172-181.
38. Graeven,U. et al. (2000) Expression patterns of placenta growth factor in human melanocytic cell lines. J. Invest. Dermatol., 115, 118-123.
39. Carmeliet,P. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, 435-439.
40. Ferrara,N. et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 380, 439-442.
41. Stetler-Stevenson,W.G. (2008) The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev., 27, 57-66.
42. Bergers,G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2, 737-744.
43. Handsley,M.M. et al. (2005) Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer, 115, 849-860.
44. Stearns,M.E. et al. (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissueinhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin. Cancer Res., 5, 189-196.
45. Swinson,D.E. et al. (2004) Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer, 111, 43-50.
46. Clottes,E. (2005) [Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy]. Bull. Cancer, 92, 119-127.
47. Treins,C. et al. (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem., 277, 27975-27981.
48. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
49. Richard,D.E. et al. (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem., 274, 32631-32637.
50. Walker,E.H. et al. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 6, 909-919.